BioCentury | Sep 1, 2014
Company News

Acrux management update

Acrux Ltd. (ASX:ACR), Melbourne, Australia Business: Drug delivery Hired: Michael Kotsanis, chief commercial officer of Synthon B.V. , as CEO and managing director, effective Nov. 3; he will succeed Ross Dobinson, who will remain chairman Resigned:...
BioCentury | Feb 18, 2013
Clinical News

Androxal enclomiphene: Completed Phase III enrollment

...see BioCentury, Feb. 4). Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) has worldwide rights from Acrux Ltd....
BioCentury | Jun 11, 2012
Clinical News

Axiron testosterone regulatory update

...Acrux to the testosterone metered-dose lotion applied to the underarm (see BioCentury, March 22, 2010). Acrux Ltd....
BioCentury | Dec 5, 2011
Clinical News

EvaMist regulatory update

...masses and gynecomastia have been reported in children following unintentional secondary exposure to the drug. Acrux...
...animals through skin contact that could result in adverse effects (see BioCentury, Aug. 9, 2010). Acrux Ltd....
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

...fever U.S. (11/2/10) 18% Acorda Therapeutics Inc. (NASDAQ:ACOR) Ampyra dalfampridine Multiple sclerosis U.S. (1/22/10) 16% Acrux Ltd....
BioCentury | Jun 6, 2011
Finance

Prima targets NASDAQ

...forward to when Prima may gain a partnership, Rogers noted that Australian drug delivery play Acrux Ltd....
...million of the US$137 million in the first two milestone payments Acrux received from Lilly. Acrux...
BioCentury | Apr 11, 2011
Company News

Acrux, Eli Lilly sales and marketing update

...to the underarm from Acrux. Further terms were not disclosed (see BioCentury, Dec. 6, 2010). Acrux Ltd....
BioCentury | Jan 10, 2011
Finance

Buyside View XIX: Commercial Risk

...NASDAQ:ACOR) Ampyra dalfampridine (formerly Fampridine-SR) Improve walking ability in patients with multiple sclerosis (MS) U.S. Acrux Ltd....
BioCentury | Jan 3, 2011
Finance

Trickle-down effect

...13% BioCentury Europe 15% 3% NYSE Arca Pharmaceutical -1% -1% 4Q approvals/4Q setbacks Company Approval Acrux Ltd....
BioCentury | Dec 6, 2010
Finance

Regulatory milestones

...Regulatory milestones Regulatory, clinical and other news for the two weeks ending Dec. 3. Acrux Ltd. (ASX:ACR...
Items per page:
1 - 10 of 77
BioCentury | Sep 1, 2014
Company News

Acrux management update

Acrux Ltd. (ASX:ACR), Melbourne, Australia Business: Drug delivery Hired: Michael Kotsanis, chief commercial officer of Synthon B.V. , as CEO and managing director, effective Nov. 3; he will succeed Ross Dobinson, who will remain chairman Resigned:...
BioCentury | Feb 18, 2013
Clinical News

Androxal enclomiphene: Completed Phase III enrollment

...see BioCentury, Feb. 4). Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) has worldwide rights from Acrux Ltd....
BioCentury | Jun 11, 2012
Clinical News

Axiron testosterone regulatory update

...Acrux to the testosterone metered-dose lotion applied to the underarm (see BioCentury, March 22, 2010). Acrux Ltd....
BioCentury | Dec 5, 2011
Clinical News

EvaMist regulatory update

...masses and gynecomastia have been reported in children following unintentional secondary exposure to the drug. Acrux...
...animals through skin contact that could result in adverse effects (see BioCentury, Aug. 9, 2010). Acrux Ltd....
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

...fever U.S. (11/2/10) 18% Acorda Therapeutics Inc. (NASDAQ:ACOR) Ampyra dalfampridine Multiple sclerosis U.S. (1/22/10) 16% Acrux Ltd....
BioCentury | Jun 6, 2011
Finance

Prima targets NASDAQ

...forward to when Prima may gain a partnership, Rogers noted that Australian drug delivery play Acrux Ltd....
...million of the US$137 million in the first two milestone payments Acrux received from Lilly. Acrux...
BioCentury | Apr 11, 2011
Company News

Acrux, Eli Lilly sales and marketing update

...to the underarm from Acrux. Further terms were not disclosed (see BioCentury, Dec. 6, 2010). Acrux Ltd....
BioCentury | Jan 10, 2011
Finance

Buyside View XIX: Commercial Risk

...NASDAQ:ACOR) Ampyra dalfampridine (formerly Fampridine-SR) Improve walking ability in patients with multiple sclerosis (MS) U.S. Acrux Ltd....
BioCentury | Jan 3, 2011
Finance

Trickle-down effect

...13% BioCentury Europe 15% 3% NYSE Arca Pharmaceutical -1% -1% 4Q approvals/4Q setbacks Company Approval Acrux Ltd....
BioCentury | Dec 6, 2010
Finance

Regulatory milestones

...Regulatory milestones Regulatory, clinical and other news for the two weeks ending Dec. 3. Acrux Ltd. (ASX:ACR...
Items per page:
1 - 10 of 77